Please use this identifier to cite or link to this item:
Title: Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death
Authors: Silva, Lígia C. Gomes da 
Kepp, Oliver
Kroemer, Guido
Keywords: Cetuximab saratolacan; photosensitizer IR700; EGFR; immunogenic cell death; head and neck cancer
Issue Date: 27-Oct-2020
Publisher: Taylor & Francis
Serial title, monograph or event: OncoImmunology
Volume: 9
Issue: 1
Abstract: In September 2020, the Japanese government approved cetuximab saratolacan (previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable locally advanced or recurrent head and neck cancer. Cetuximab saratolacan is a chemical conjugate of the photosensitizer IR700 with cetuximab, which targets EGFR. The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of the tumor with red light (690 nm) for photodynamic therapy. This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response.
ISSN: 2162-4011
DOI: 10.1080/2162402X.2020.1841393
Rights: openAccess
Appears in Collections:I&D CQC - Artigos em Revistas Internacionais

Show full item record

Page view(s)

checked on Feb 28, 2024


checked on Feb 28, 2024

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons